← Back to Analyst Consensus 
INDV Buy
Indivior Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 5, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jun 18, 2026 | Barclays | initiate | — → Overweight | — | 53% |
| Jan 12, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $48 | 44% |
| Oct 31, 2025 | Piper Sandler | reiterate | Overweight → Overweight | $41 | 54% |
| Oct 30, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $35 | 44% |
| Aug 27, 2025 | Craig-Hallum | maintain | Buy → Buy | $34 | 54% |
| Aug 6, 2025 | HC Wainwright & Co. | initiate | — → Buy | $28 | 44% |
| Jun 30, 2025 | Craig-Hallum | maintain | Buy → Buy | $22 | 54% |
| Mar 6, 2025 | Piper Sandler | maintain | Overweight → Overweight | $13 | 54% |
| Oct 25, 2024 | Piper Sandler | reiterate | Overweight → Overweight | $16 | 54% |
| Oct 11, 2024 | Craig-Hallum | maintain | Buy → Buy | $16 | 54% |
| Oct 11, 2024 | Piper Sandler | reiterate | Overweight → Overweight | $15 | 54% |
| Sep 13, 2024 | Piper Sandler | reiterate | Overweight → Overweight | $22 | 54% |
| Jul 23, 2024 | Piper Sandler | initiate | — → Overweight | $22 | 54% |
| Jul 10, 2024 | Craig-Hallum | maintain | Buy → Buy | $24 | 54% |
| Apr 3, 2024 | Craig-Hallum | initiate | — → Buy | $37 | 54% |
Price Target Trend
May 25, 2026 Latest: $49 Oct 25, 2026
EPS Estimates
+1y $4.88
Lo: $4.74 Hi: $5.02
3 analysts ▲2
+1q $1.21
Lo: $1.21 Hi: $1.22
2 analysts ▲2
0y $4.41
Lo: $4.36 Hi: $4.47
3 analysts 0q $1.12
Lo: $1.09 Hi: $1.15
2 analysts ▲2
Cross-Platform Signals
No cross-platform signals in the last 90 days